• Applied Workflows with Bromodomain Inhibitor (+)-JQ1: BET Ta

  2026-06-03

  Bromodomain Inhibitor (+)-JQ1 empowers researchers with precise, reproducible BET protein inhibition across oncology, inflammation, and male contraception models. This guide unpacks practical workflows, troubleshooting, and data-backed advantages, translating recent mechanistic discoveries into actionable protocols for advanced research.

• Caffeine (1,3,7-trimethylpurine-2,6-dione): Innovations in M

  2026-06-03

  Discover the multifaceted research applications of Caffeine (1,3,7-trimethylpurine-2,6-dione), highlighting its advanced role in cancer inhibition, metabolic regulation, and cross-domain translational science. This article offers a uniquely integrated, evidence-driven perspective for scientists seeking optimized protocols.

• Personalized iPSC Platforms for Ultrarare Disease Trial Sele

  2026-06-02

  This study demonstrates the creation of a patient-specific induced pluripotent stem cell (iPSC) platform to evaluate drug efficacy for an individual with an ultrarare Leigh-like syndrome. The approach enables tailored prescreening of therapies, helping guide clinical trial decisions in cases where standard evidence is lacking.

• Applied Workflows with the Reactive Oxygen Species Assay Kit

  2026-06-02

  Unlock robust, quantitative superoxide detection in living cells with the Reactive Oxygen Species Assay Kit (DHE). This guide delivers stepwise protocols, advanced applications, and troubleshooting insights, translating cutting-edge immunomodulatory research into actionable ROS assay workflows.

• Staurosporine: Broad-Spectrum Protein Kinase Inhibitor in Ca

  2026-06-01

  Staurosporine’s unmatched potency as a broad-spectrum serine/threonine protein kinase inhibitor enables precise induction of apoptosis and robust kinase pathway mapping in cancer cell lines. Recent high-throughput imaging protocols now empower researchers to quantify and optimize fractional cell killing, maximizing the translational impact of Staurosporine in tumor and angiogenesis studies.

• Strategic Innovation in mRNA Delivery: Dual-Mode Tracking Re

  2026-06-01

  This thought-leadership article explores how dual-reporter, 5-moUTP-modified mRNA technologies—exemplified by APExBIO's EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)—are redefining mRNA delivery, tracking, and translational research workflows. By integrating mechanistic insight, competitive context, and guidance on experimental design, it uniquely bridges the latest advances in non-viral delivery, immune evasion, and real-time tracking, while anchoring the discussion in recent breakthroughs in metal-organic framework (MOF) encapsulation and next-generation assay paradigms.

• Rhodamine B (SKU A4705): Reliable Solutions for Cell Assays

  2026-05-31

  This article explores how Rhodamine B (SKU A4705) from APExBIO addresses common laboratory challenges in cell viability, proliferation, and cytotoxicity assays. Scenario-driven Q&A blocks deliver evidence-based guidance for protocol design, data interpretation, and reagent selection, supporting reproducible and sensitive research workflows.

• CCCP (carbonyl cyanide m-chlorophenyl hydrazine): Reliable M

  2026-05-30

  This article addresses practical laboratory challenges in assessing mitochondrial function and viability using CCCP (carbonyl cyanide m-chlorophenyl hydrazine), emphasizing SKU B5003 from APExBIO. Through scenario-driven Q&A, we outline how CCCP delivers reproducible, data-backed solutions for mitochondrial uncoupling, supporting robust cell-based assays and advanced disease modeling.

• FGF19-ELF4 Axis Drives Colorectal Cancer Metastasis via SRC

  2026-05-29

  The referenced study delineates a novel metastatic mechanism in colorectal cancer, showing that FGF19-mediated upregulation of ELF4 promotes metastasis through direct activation of FGFR4 and SRC. These findings establish the ELF4/FGFR4/SRC axis as a potential therapeutic target and provide mechanistic rationale for Src kinase inhibition in advanced colorectal cancer.

• Translating Dual-Action p38 MAPK Inhibition with Losmapimod

  2026-05-29

  Explore how Losmapimod (GW856553X) is reshaping translational research on inflammation and vascular disease by leveraging both direct kinase inhibition and the emerging paradigm of conformational control over dephosphorylation. Integrating mechanistic evidence and practical workflow insights, this article guides investigators toward robust, reproducible outcomes in hypertension and COPD studies, while highlighting APExBIO’s leadership and the next frontiers in p38 MAPK pathway modulation.

• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-05-28

  Schwartz's dissertation advances the evaluation of anti-cancer drug responses by dissecting the distinct and often conflated measures of cell proliferation arrest and cell death in vitro. This nuanced approach provides researchers with more reliable tools to characterize the efficacy of apoptosis inducers and growth inhibitors, informing better translational decision-making for oncology drug discovery.

• 3D Organoid–Fibroblast Co-Cultures Reveal Chemoresistance in

  2026-05-28

  Schuth et al. developed a patient-specific three-dimensional co-culture model incorporating both pancreatic ductal adenocarcinoma (PDAC) organoids and matched cancer-associated fibroblasts (CAFs), allowing direct investigation of stromal contributions to chemoresistance. Their findings highlight the pivotal role of CAF-driven epithelial-to-mesenchymal transition (EMT) and pro-inflammatory activation in mediating reduced drug sensitivity, advancing the fidelity of preclinical drug screening for PDAC.

• Neurotensin (CAS 39379-15-2): Reliable Solutions for GPCR &

  2026-05-27

  This article provides a scenario-driven, evidence-based guide for leveraging Neurotensin (CAS 39379-15-2) (SKU B5226) in cell viability, proliferation, and cytotoxicity assays. It explores practical workflow challenges, data quality comparisons, and vendor reliability, demonstrating how APExBIO's high-purity Neurotensin enables reproducible GPCR trafficking and miRNA regulation studies.

• Deferasirox Fe3+ Chelate: Lysosomal Iron Handling in Iron Ov

  2026-05-27

  Explore how Deferasirox Fe3+ chelate advances iron overload treatment research by enabling precise investigation of lysosomal iron metabolism. This in-depth article uniquely connects chelation mechanisms to metabolic adaptation, providing new perspectives for chronic anemia and beta-thalassemia studies.

• 740 Y-P: Reliable PI 3-Kinase Activator for Cell Assay Preci

  2026-05-26

  This article delivers a scenario-driven, evidence-based exploration of 740 Y-P (SKU B5246) as a potent PI 3-kinase activator for cell viability, apoptosis, and vesicular trafficking research. Designed for biomedical researchers and technicians, it details protocol parameters, data interpretation, and product selection criteria to enhance reproducibility and experimental clarity in PI3K/AKT pathway studies.

16182 records 1/1079 page Next 12345 下5页 Last page